Graft-versus-host disease (GVHD) results from recognition of host antigens by donor T cells following allogeneic hematopoietic cell transplantation (AHCT). Notably, histoincompatibility between donor and recipient is necessary but not sufficient to elicit GVHD. Therefore, we tested the hypothesis that some donors may be “stronger alloresponders” than others, and consequently more likely to elicit GVHD. T cells from 50 AHCT donors with microarrays. We report that pre-AHCT gene-expression profiling segregates donors whose recipient suffered from GVHD or not. Using quantitative PCR, established statistical tests, and analysis of multiple independent training-test datasets, we found that for chronic GVHD the “dangerous donor” trait (occurrence ...
BACKGROUND: The major histocompatibility complex (MHC) is the most important genomic region that con...
Currently, the pathogenesis of chronic GVHD is unclear. To elucidate the molecular characteristics u...
Despite detailed human leukocyte antigen (HLA) matching and modern immunosuppressive therapy, severe...
Chronic graft-versus-host disease (GVHD) results in significant morbidity and mortality, limiting th...
International audienceThe cellular and molecular processes involved in acute graft-versus-host disea...
International audienceThe cellular and molecular processes involved in acute graft-versus-host disea...
International audienceHematopoietic stem cell (HSC) allograft can be performed with cells of periphe...
International audienceHematopoietic stem cell (HSC) allograft can be performed with cells of periphe...
The persistence of graft-versus-host disease (GVHD) as the principal complication of allogeneic hema...
The major histocompatibility complex (MHC) is the most important genomic region that contributes to ...
Acute graft-versus-host disease (GVHD) afflicts up to 80 % of all patients receiving an unrelated do...
Despite considerable advances in our understanding of the pathophysiology of graft-versus-host disea...
Graft-vs.-host disease (GvHD) is a major complication after allogeneic hematopoietic stem cell trans...
Despite matching donors and recipients for the human leukocyte antigens (HLAs) expressed by the majo...
Background: The major histocompatibility complex (MHC) is the most important genomic region that con...
BACKGROUND: The major histocompatibility complex (MHC) is the most important genomic region that con...
Currently, the pathogenesis of chronic GVHD is unclear. To elucidate the molecular characteristics u...
Despite detailed human leukocyte antigen (HLA) matching and modern immunosuppressive therapy, severe...
Chronic graft-versus-host disease (GVHD) results in significant morbidity and mortality, limiting th...
International audienceThe cellular and molecular processes involved in acute graft-versus-host disea...
International audienceThe cellular and molecular processes involved in acute graft-versus-host disea...
International audienceHematopoietic stem cell (HSC) allograft can be performed with cells of periphe...
International audienceHematopoietic stem cell (HSC) allograft can be performed with cells of periphe...
The persistence of graft-versus-host disease (GVHD) as the principal complication of allogeneic hema...
The major histocompatibility complex (MHC) is the most important genomic region that contributes to ...
Acute graft-versus-host disease (GVHD) afflicts up to 80 % of all patients receiving an unrelated do...
Despite considerable advances in our understanding of the pathophysiology of graft-versus-host disea...
Graft-vs.-host disease (GvHD) is a major complication after allogeneic hematopoietic stem cell trans...
Despite matching donors and recipients for the human leukocyte antigens (HLAs) expressed by the majo...
Background: The major histocompatibility complex (MHC) is the most important genomic region that con...
BACKGROUND: The major histocompatibility complex (MHC) is the most important genomic region that con...
Currently, the pathogenesis of chronic GVHD is unclear. To elucidate the molecular characteristics u...
Despite detailed human leukocyte antigen (HLA) matching and modern immunosuppressive therapy, severe...